Clinical Trial Update: A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and tolerability study in mild to moderate Alzheimer's disease was terminated; sponsor was Janssen Alzheimer's Immunotherapy Research &…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED